Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 2/20 | 0.57 |
| ▸ | PRKD1 | Q15139 | 14/20 | 0.55 |
| ▸ | PRKD2 | Q9BZL6 | 10/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1579219 | 0.87 | PRKD1 (0.71) | KARS1PRKD1PRKD2ADRB1 | |
| SCHEMBL1579182 | 0.86 | PRKD1 (0.65) | PRKD1PRKD2ADRB1 | |
| SCHEMBL1579619 | 0.84 | PRKD1 (0.59) | PRKD1PRKD2ADRB1CCNT1 | |
| SCHEMBL1592056 | 0.81 | PRKD1 (0.81) | PRKD1PRKD2ADRB1 | |
| SCHEMBL1580957 | 0.78 | PRKD1 (0.55) | PRKD1PRKD2ADRB1CCNT1 | |
| SCHEMBL1192258 | 0.77 | CCNT1 (0.55) | KARS1PRKD1PRKD2CCNT1 | |
| SCHEMBL1192376 | 0.77 | CCNT1 (0.72) | CCNT1 | |
| SCHEMBL1579448 | 0.76 | PRKD1 (0.69) | KARS1PRKD1PRKD2ADRB1CCNT1 | |
| SCHEMBL7948438 | 0.74 | PRKD1 (0.75) | PRKD1PRKD2ADRB1CCNT1 | |
| SCHEMBL12898597 | 0.74 | CCNT1 (0.61) | PRKD1PRKD2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | KARS1 3287/4885PRKD1 4750/4885PRKD2 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.